Calliditas Therapeutics

• Directed share issue of 2,400,000 new shares at a placement price of SEK 135 per share, generating gross proceeds of SEK 324 million
• Calliditas Therapeutics’ capital increase was upsized during bookbuilding to SEK 324 million from originally SEK 300 million at launch, representing a total increase of the company’s share capital by 4.6%
• The placement price represents a discount of 4.8% vis-à-vis the closing price prior to transaction announcement
• Calliditas Therapeutics intends to use the net proceeds to fund ongoing clinical development, pre-commercial development in the US, commercial activities for Nefecon, if approved for marketing by the FDA, and general corporate purposes
• Following our Placement Agent role in Investinor’s sell-down of c. 4 million existing Calliditas Therapeutics shares in November 2020, Kempen & Co is proud to have assisted Calliditas Therapeutics in this capital increase
• In 2021 year to date, Kempen & Co has executed 8 transactions for Nordic life sciences companies and 11 transaction for other European life sciences companies

Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercialising novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of adults with the autoimmune renal disease primary IgA nephropathy (IgAN), for which there is a high unmet medical need and there are no approved treatments. Calliditas has recently read out topline data from Part A of its global Phase III study in IgAN and, if approved, aims to commercialise Nefecon in the United States. Calliditas is also planning to start clinical trials with NOX inhibitors in primary biliary cholangitis and head and neck cancer. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT)

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise.
Recent transactions include:

• Joint Global Coordinator & Joint Bookrunner in the SEK 380 million Capital Increase by Xbrane Biopharma
• Joint Global Coordinator in the €34.1m Capital Increase by Transgene
• Joint Global Coordinator & Joint Bookrunner in the SEK 141 million Capital Increase by Immunicum
• Lead Manager in the USD 63.8 million Nasdaq Initial Public Offering by Molecular Partners
• Joint Bookrunner in the SEK 301 million Capital Increase by Q-linea
• Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
• Joint Bookrunner in the €30.0 million Capital Increase by GenSight Biologics
• Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
• Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Oncopeptides
• Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
• Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
• Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
• Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
• Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
• Bookrunner in the USD 518 million US Public Offering by CureVac
• Lead Manager in the USD 120 million US Public Offering by Merus 
• Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
• Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
• Financial Adviser to DCprime in its merger with Immunicum 
• Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
• Lead Manager in the USD 95.1 million Nasdaq Initial Public Offering by Galecto
• Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
• Bookrunner in the USD 245 million Nasdaq Initial Public Offering by CureVac

Please do not hesitate to contact us if you have further questions.